nafamostat has been researched along with Guillain-Barre Syndrome in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phongsisay, V | 1 |
| Susuki, K | 1 |
| Matsuno, K | 1 |
| Yamahashi, T | 1 |
| Okamoto, S | 1 |
| Funakoshi, K | 1 |
| Hirata, K | 1 |
| Shinoda, M | 1 |
| Yuki, N | 1 |
1 other study available for nafamostat and Guillain-Barre Syndrome
| Article | Year |
|---|---|
Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.
Topics: Animals; Benzamidines; Complement C3; Complement Inactivating Agents; Disease Models, Animal; Guanid | 2008 |